Atle Fund Management AB Buys 5,031 Shares of DexCom, Inc. $DXCM

Key Points

• Atle Fund Management AB increased its investment in DexCom, Inc. by 11%, now holding 50,872 shares worth approximately $4.44 million, making it the 21st largest holding in their portfolio.
• DexCom saw its stock drop by 11.0%, with shares trading at $67.45, while the company reported a revenue of $1.16 billion for the quarter, exceeding estimates.
• Analysts have mixed ratings on DexCom, with a general consensus leaning towards a "Moderate Buy" rating and an average price target of $99.89.

Atle Fund Management AB increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 11.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,872 shares of the medical device company's stock after acquiring an additional 5,031 shares during the period. DexCom comprises about 1.9% of Atle Fund Management AB's holdings, making the stock its 21st largest holding. Atle Fund Management AB's holdings in DexCom were worth $4,441,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Baader Bank Aktiengesellschaft purchased a new stake in shares of DexCom during the second quarter valued at approximately $393,000. Mn Services Vermogensbeheer B.V. raised its holdings in DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company's stock valued at $12,797,000 after buying an additional 6,800 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in DexCom by 85.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company's stock valued at $105,469,000 after buying an additional 557,576 shares during the period. Golden State Wealth Management LLC boosted its position in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares during the period. Finally, Private Trust Co. NA grew its holdings in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on DXCM. Argus initiated coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price objective for the company. Mizuho boosted their price target on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. William Blair upgraded DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Piper Sandler lifted their price objective on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Finally, The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $99.89.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,315 shares of company stock valued at $689,431 in the last ninety days. Corporate insiders own 0.32% of the company's stock.

DexCom Stock Down 1.2%

Shares of DXCM stock traded down $0.83 during mid-day trading on Tuesday, hitting $68.68. The company's stock had a trading volume of 2,827,460 shares, compared to its average volume of 4,113,654. The stock has a market cap of $26.93 billion, a price-to-earnings ratio of 47.71, a PEG ratio of 1.41 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The business has a 50-day moving average price of $79.59 and a 200 day moving average price of $78.19.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm earned $0.43 earnings per share. The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.